- Home
- EQR vs NTRA Comparison
EQR vs NTRA Comparison
Compare EQR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- NTRA
- Stock Information
- Founded
- EQR 1993
- NTRA 2003
- Country
- EQR United States
- NTRA United States
- Employees
- EQR N/A
- NTRA N/A
- Industry
- EQR Real Estate Investment Trusts
- NTRA Medical Specialities
- Sector
- EQR Real Estate
- NTRA Health Care
- Exchange
- EQR Nasdaq
- NTRA Nasdaq
- Market Cap
- EQR 23.8B
- NTRA 21.7B
- IPO Year
- EQR 1993
- NTRA 2015
- Fundamental
- Price
- EQR $64.12
- NTRA $163.02
- Analyst Decision
- EQR Buy
- NTRA Strong Buy
- Analyst Count
- EQR 14
- NTRA 16
- Target Price
- EQR $77.61
- NTRA $193.50
- AVG Volume (30 Days)
- EQR 2.4M
- NTRA 1.7M
- Earning Date
- EQR 08-04-2025
- NTRA 08-07-2025
- Dividend Yield
- EQR 4.32%
- NTRA N/A
- EPS Growth
- EQR 5.58
- NTRA N/A
- EPS
- EQR 2.65
- NTRA N/A
- Revenue
- EQR $3,044,764,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- EQR $5.13
- NTRA $19.98
- Revenue Next Year
- EQR $4.28
- NTRA $16.16
- P/E Ratio
- EQR $24.16
- NTRA N/A
- Revenue Growth
- EQR 4.40
- NTRA 44.38
- 52 Week Low
- EQR $59.41
- NTRA $110.57
- 52 Week High
- EQR $78.84
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- EQR 45.28
- NTRA 65.28
- Support Level
- EQR $62.09
- NTRA $152.62
- Resistance Level
- EQR $64.03
- NTRA $161.92
- Average True Range (ATR)
- EQR 1.32
- NTRA 6.11
- MACD
- EQR 0.05
- NTRA 3.42
- Stochastic Oscillator
- EQR 39.30
- NTRA 93.78
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.